Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 22, Issue 7, pp. 1553-1558
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 13, 2015
- Revision received December 22, 2015
- Accepted December 24, 2015
- Published first January 12, 2016.
Article Versions
- Previous version (January 12, 2016 - 10:19).
- You are viewing the most recent version of this article.
Copyright & Usage
©2016 American Association for Cancer Research.
Author Information
- Paul G. Kluetz1,*,
- Ashley Slagle2,
- Elektra J. Papadopoulos2,
- Laura Lee Johnson3,
- Martha Donoghue1,
- Virginia E. Kwitkowski1,
- Wen-Hung Chen2,
- Rajeshwari Sridhara3,
- Ann T. Farrell1,
- Patricia Keegan1,
- Geoffrey Kim1, and
- Richard Pazdur1
- 1Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- 2Clinical Outcome Assessment Staff, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- 3Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- ↵*Corresponding Author:
Paul G. Kluetz, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO22 Room 2223, Silver Spring, MD 20993. E-mail: paul.kluetz{at}fda.hhs.gov
April 2016
Volume 22, Issue 7
Volume 22, Issue 7
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Jump to section
Advertisement